Lou J, Lv JX, Zhang YP, Liu ZJ. OSI-027 inhibits the tumorigenesis of colon cancer through mediation of c-Myc/FOXO3a/PUMA axis.
Cell Biol Int 2022;
46:1204-1214. [PMID:
35293663 DOI:
10.1002/cbin.11792]
[Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/22/2021] [Revised: 01/16/2022] [Accepted: 03/13/2022] [Indexed: 11/07/2022]
Abstract
Colon cancer is a gastrointestinal malignancy which is one of the leading causes of tumor-associated deaths. It has been reported that mTOR can lead to the progression of colon cancer. However, the mechanism by which mTOR inhibitor (OSI-027) mediates the tumorigenesis of colon cancer remains largely unknown. Cell function of colon cancer was investigated by CCK-8 flow cytometry and TUNEL staining. In addition, qRT-PCR and western blot were used to investigate the mechanism underlying the function of OSI-027 in colon cancer. OSI-027 dose-dependently reduced colon cancer cell viability through inducing the cell apoptosis. In addition, OSI-027 induced the apoptosis of colon cancer cells via upregulation of PUMA. OSI-027 promoted the expression of PUMA by activation of FOXO3a, and c-Myc knockdown partially increased FOXO3a and PUMA level. Moreover, OSI-027 attenuated the tumor growth of colon cancer through mediation of mTOR/c-Myc/FOXO3a axis. OSI-027 attenuates colon cancer progression through mediation of c-Myc/FOXO3a/PUMA axis. Thereby, this research might shed new insights on exploring the strategies against colon cancer. This article is protected by copyright. All rights reserved.
Collapse